#United Kingdom #Piramal Pharma #Korsch XM-12 #Morpeth

Piramal Pharma Solutions Enhances Formulation Capabilities

Piramal Pharma Solutions, a renowned leader in Contract Development and Manufacturing Organization (CDMO) services, has announced the acquisition of a cutting-edge Korsch XM-12 bilayer tablet press at its facility in Morpeth, UK. This advancement plays a crucial role in the company’s integrated offering, particularly in the development and production of solid dosage forms and hormone products.

With the addition of the Korsch XM-12, the formulation development team at the Morpeth site can now achieve high tablet output with increased precision and efficiency for both single-layer and bilayer production. Engineered with advanced features, the XM-12 includes specialized sanitary fittings for the feed hoppers, a dedicated chute for handling potent active ingredients, and quick-change tooling for rapid format changes.

Commitment to Safety and Quality

Piramal Pharma Solutions prioritizes safety and high-quality output with the implementation of comprehensive training protocols for the XM-12. The company ensures safe operation and optimal performance of the new machinery. Frank Bugg, Managing Director and Site Head at Morpeth, emphasizes the thorough training regiment that the scientists, operators, and maintenance teams will undergo.

"In preparation for utilizing the Korsch XM-12, our team will receive tailored training, in collaboration with Korsch technicians, to ensure everyone understands the machine’s operations and capabilities. Additionally, our validation experts will oversee the qualification and validation processes to ensure compliance with both industry standards and Piramal's stringent quality requirements," explained Bugg.

The training will cater specifically to the unique needs of staff involved in formulation development, technical transfers, and maintenance, ensuring that they are well-equipped to handle both bilayer and single-layer processes effectively.

Features of the Korsch XM-12

The Korsch XM-12 is designed with integrated technology that delivers consistently precise outputs while minimizing operator intervention after critical settings are established. This innovation signifies Piramal’s ongoing commitment to advancing drug delivery systems and improving patient care by enhancing quality and efficiency across all operations.

With the capability to produce high-quality tablets at scale, the Korsch XM-12 will significantly enhance the Morpeth facility’s ability to serve varying patient needs through innovative therapies. This strategic investment not only supports Piramal Pharma Solutions in delivering drugs more effectively but also contributes to the reduction of global disease burden.

About Piramal Pharma Solutions

Piramal Pharma Solutions operates as a full-service CDMO, providing end-to-end development and manufacturing solutions throughout the pharmaceutical lifecycle. With a global network of facilities in North America, Europe, and Asia, the company offers an extensive array of services, including drug research, process development, clinical trial supplies, and commercial API delivery. Their specialized services extend to areas such as potent API development, antibody-drug conjugates, sterile filling, and solid oral dosage forms. Notably, Piramal also provides services for biologics, focusing on vaccines and gene therapies, facilitated by investments in innovative biotechnology companies.

In summary, the installation of the Korsch XM-12 bilayer tablet press at Piramal’s Morpeth site exemplifies the company's commitment to leveraging technological advancements to improve drug formulation capabilities and patient outcomes. As the pharmaceutical landscape continues to evolve, Piramal remains focused on its mission to deliver quality healthcare solutions worldwide.